Has this FTSE 100 favourite hit its pinnacle?

This FTSE 100 (INDEXFTSE: UKX) engineering favourite has seen expansion and a rising share price this year, but can it continue?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Spirax Sarco Engineering (LSE:SPX) is a venerable company (130 years-old) with a fascinating history. So interesting in fact, it has an entire book written about it (Knowledge, Service, Products: The History of Spirax-Sarco Engineering by Nigel Watson). 

It was first quoted on the London Stock Exchange in 1959 and now employs over 7,500 people worldwide, serves over 100,000 direct-buying customers, and has over 1,500 core product lines. It reached another significant milestone when it was promoted to the FTSE 100 on Christmas Eve 2018. Since then, the share price has steadily climbed, peaking at £94 in early July and its year-end report has pleased existing shareholders. However, I’m not sure the company is set up to sustain this recent success, so let’s take a look.

Financial overview

With a trailing 12-month price-to-earnings ratio (P/E) of 29, this is much higher than the average of 17.9 for this industry. Nevertheless, its average P/E over the past five years has been just under 25, which is not significantly lower so maybe it could still climb?

But there are other metrics that suggest it might not. Spirax Sarco’s debt ratio is 51% which is greater than the recommended peak of 40%, and its level of debt has increased from 25% over the past five years. That said, operating cash flow more than covers the total debt and interest payments on debt are covered by earnings.

As the debt has increased, so has the share price, so the company has been doing something right. It saw an outstanding increase of 41% in EPS in the last year but this was due to acquisitions and panic-buying customers worried about Brexit, as well as strong organic sales growth of over 7%. 

Spirax Sarco has a pretty poor dividend yield of 1.1% but it has remained stable and consistent over the past 50 years.

Opportunities ahead

The company argues that it still has immense opportunities ahead for growth, holding only a 14% share of the world markets (worth £8.5bn) it is involved in.

The success of recent expansion into emerging markets, in countries such as Myanmar, Peru and Indonesia, remains to be seen. Although emerging markets can offer untapped opportunities and riches, they can also be risky, especially given the fragility of the world stage today.

Gaining new businesses and technologies is usually a positive action, but could this have stretched the group’s finances a step too far? This business is not averse to cyclical pressures and current margins offer limited expansion potential.

The company prides itself on its direct selling approach and this, along with strong relationships, long-term vision and employee appreciation, contributes to the strength of the business and backs up its resilience to economic disruption. In theory, it should be well-positioned to grow and develop into the future. However, analysts have been backing off lately, with a general feeling that the share is now overvalued and its price is too high.

Given that this engineering firm has done so well recently but has nothing outstanding in the pipeline to continue this rise, along with its pathetic dividend offering, I’m inclined to avoid it for now. I also worry it could be ready to take a big tumble if a recession rears its ugly head.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »